Oncology clinical trials represent a special challenge for biopharmaceutical companies. When oncology research sites enroll, it takes an average of more than eight months from protocol outreach to site activation, and 60 percent of the sites never enroll a single patient. In fact, 40 percent of current ongoing trials will not meet their enrollment targets.

1. https://www.forbes.com/sites/judystone/2015/01/06/how-can-we-encourage-participation-in-clinical-trials/#ldc9f1ac4d0c
ONCOLOGY
ENROLLMENT ENHANCEMENT

250+ pre-qualified sites
1,000+ investigators

Oncology enrollment enhancement uses a just-in-time methodology to jump-start study enrollment, with no risk for clients. We provide a price structure based on confirmed availability of preidentified patients from prequalified sites in our community of over 250 sites with over 1,000 research-experienced investigators. This turnkey service augments your traditional trial approach and provides the first study subject within two weeks of patient identification.

THE JUST-IN-TIME APPROACH

Community of sites with prenegotiated contracts / terms
Immediate engagement by sites to search for patients
Patients identified and site activated
Patients enrolled within two weeks of identification *

*Zero non-enrolling sites in the just-in-time community

OPTIMIZING DIVERSITY, EFFICIENCY AND PATIENT CENTRICITY THROUGH THE JUST-IN-TIME COMMUNITY

Patients get the treatment they need in the communities where they live from the physicians they trust surrounded by the people they love

Hospital Systems | 18%
Academic Centers | 6%
Private Practices | 76%
INCORPORATING OPPORTUNITY, LOWERING RISK

Just-in-time enrollment augments your existing approach with prequalified sites and prequalified patients.

Risk mitigation strategy is available from day one.

THE JUST-IN-TIME APPROACH IN ACTION

DAYS FROM PATIENT IDENTIFIED TO ENROLLED:

- **10** Metastatic Breast Cancer: PHASE II
- **10** Neutropenia Breast Cancer: PHASE III
- **4** ALK+ NSCLC: PHASE III
- **10** Basket Trial: Solid Tumors: PHASE II
- **7** NSCLC HLAA2+: PHASE III
ENROLLMENT BENEFITS

**Diversity**
Just-in-time sites are concentrated in ethnically diverse areas, helping expand access to underserved, minority populations.

**Patient-centric**
Exposing more trial options to patients where they live while allowing sites to focus on studies for which they have patients.

**Efficiency**
Improved efficiencies/volume through protocol stacking.

**Performance**
Opportunity to accelerate overall study performance.

**Enrollment Timeline**
First patient within two weeks of patient identification.

**Risk Management**
Mitigate risk from non-enrolling sites; risk mitigation strategy is available from day one.

CONSIDER JUST-IN-TIME FOR:

- Portfolio programs leveraging multiple indications
- Basket programs
- Biomarker-driven trials
- Clinical programs where first patient in (FPI) is a critical event
- Highly competitive research areas including cutting-edge technology
- Second-line treatments where patients can be preidentified and followed to progression
- Indications where patients may prefer treatment near home